Form 4: InnovAge Director Richard Zoretic Granted Future Restricted Stock Units

InnovAge Holding Corp. Director Richard Zoretic was granted 25,316 Restricted Stock Units (RSUs) on July 1, 2025, which are scheduled to vest on June 30, 2026.

Summary

• Richard C. Zoretic, a Director of InnovAge Holding Corp. (INNV), is set to acquire 25,316 shares of common stock.
• The acquisition is scheduled for July 1, 2025, and will be in the form of Restricted Stock Units (RSUs).
• These RSUs were granted at a price of $0 per share, indicating they are part of an equity compensation plan.
• The RSUs will settle in shares of common stock and are scheduled to vest in full on June 30, 2026, contingent on Mr. Zoretic's continued service with the Issuer.
• Following this transaction, Mr. Zoretic will beneficially own 93,810 shares of InnovAge common stock directly.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units to a director is a positive sign of continued commitment and aligns the director's interests with long-term shareholder value, as vesting is contingent on continued service.

Positives

• The grant of Restricted Stock Units aligns the director's interests with long-term shareholder value.
• The vesting schedule encourages continued service and commitment from a key board member.

Negatives

• The transaction is a grant of equity compensation rather than an open market purchase, meaning no direct cash investment by the director.

Future Outlook

The granted Restricted Stock Units are scheduled to vest in full on June 30, 2026, contingent on the director's continued service with InnovAge Holding Corp.

Industry Context

This transaction is a routine insider equity compensation event, common across publicly traded companies to align executive and director incentives with shareholder interests.

Comparison to Industry Standards

• The grant of Restricted Stock Units to a director is a standard practice in corporate governance, aligning the director's long-term interests with the company's performance.
• While specific grant sizes vary by company size and industry, equity compensation is a common component of director remuneration across the healthcare services sector.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on employees is indicated by this specific transaction.
• Customers: No direct impact on customers is indicated by this specific transaction.
• Suppliers: No direct impact on suppliers is indicated by this specific transaction.
• Creditors: No direct impact on creditors is indicated by this specific transaction.

Next Steps

• Vesting of 25,316 Restricted Stock Units on June 30, 2026, subject to continued service.

Key Dates

Keywords

InnovAge, INNV, Richard Zoretic, Director, Restricted Stock Units, RSU, Equity Compensation, SEC Form 4, Insider Transaction, Stock Grant